Project title: Development of sustained release ocular implants for delivery of corticosteroids and non-steroidal anti-inflammatory drugs (NSAID) to the eye for the prevention and treatment of macular oedema
In this project, PolyActiva plan to develop both steroidal and NSAID ocular implants for the short term and long-term prevention and treatment of macular oedema.
Macular oedema is a retinal disease arising from inflammation associated with ocular surgery or diabetic retinopathy.
After ocular (e.g. cataract) surgery ophthalmologists prescribed patients steroid, NSAID and antibiotic eye drops to reduce inflammation and prevent infection. Treatment in this patient population is often compromised by poor drop competence and adherence associated with patient age.
There is a significant unmet medical need for alternatives to drop therapy, such as ocular implants that can be administered at the point of surgery.
BMTH Round: Two
Project Partners:Monash Institute of Pharmaceutical Sciences at Monash University
- MTPConnect Grant: $1,000,000
- Industry Contribution: $2,394,381
Duration: April 2020 - September 2022 (Ongoing)
Contact: Russell Tait